

11 March 2020

ASX ANNOUNCEMENT

ADMEDUS RECEIVES FINAL APPROVAL BY FAMHP FOR FIRST-IN-HUMAN STUDY

Admedus Limited (ASX:AHZ) (**Admedus** or the **Company**) announces the final step for approval of the first-in-human study was granted today by the external competent authority, Federal Agency for Medicines and Health Products (FAMHP) of Belgium. This means the study can go ahead as planned in March 2020.

“Now that we have final approval to commence the study, we can move forward according to our plan with Professor Bart Meuris and his team at the University Hospitals Leuven, Belgium to perform this important study. The study will give us valuable information that will help progress our path to market,” said Chief Executive Officer, Wayne Paterson.

Additional information can be found at <https://infomeddnews.com/valve-durability-in-tavr-is-a-critical-factor-for-the-future/>

ENDS

About Admedus Limited (ASX: AHZ)

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAdmedus@we-worldwide.com
P: +61 401 018 828

www.admedus.com
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus

Admedus Limited

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299
E: info@admedus.com W: admedus.com

